Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3995
Single User License Price INR 269463
Corporate User License Price USD 11985
Corporate User License Price INR 808388
Site License Price USD 7990
Site License Price INR 538926
Request a Quote

Report Title

Menopausal Disorders Drug Development Pipeline Review, 2018

Quote Request for License Type
License Type Price  
Single User License USD 3995
Site License USD 7990
Enterprise Wide License USD 11985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Menopausal Disorders Drug Development Pipeline Review, 2018


Quote Request for License Type
License Type Price  
Single User License USD 3995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Menopausal Disorders Drug Development Pipeline Review, 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Menopausal Disorders Drug Development Pipeline Review, 2018



Executive Summary

Menopausal Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for postmenopausal osteoporosis, vaginal atrophy and vasomotor symptoms of menopause, and features dormant and discontinued products.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. There are 20 products in development for this indication.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence.

Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. There are five products in development for this indication.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders. There are 12 products in development for this indication.

Molecular targets acted on by products in development for menopausal disorders include tumor necrosis factor ligand superfamily member 11, parathyroid hormone receptor and progesterone receptor. Companies operating in this pipeline space include Amgen, TherapeuticsMD and Ipsen.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Menopausal Disorders Report Coverage 7

2.2 Post Menopausal Osteoporosis-Overview 7

2.3 Vaginal Atrophy (Atrophic Vaginitis)-Overview 7

2.4 Vasomotor Symptoms of Menopause (Hot Flashes)-Overview 7

3 Therapeutics Development 8

3.1 Post Menopausal Osteoporosis 8

3.2 Vaginal Atrophy (Atrophic Vaginitis) 12

3.3 Vasomotor Symptoms of Menopause (Hot Flashes) 15

4 Therapeutics Assessment 18

4.1 Post Menopausal Osteoporosis 18

4.2 Vaginal Atrophy (Atrophic Vaginitis) 24

4.3 Vasomotor Symptoms of Menopause (Hot Flashes) 29

5 Companies Involved in Therapeutics Development 35

5.1 Post Menopausal Osteoporosis 35

5.2 Vaginal Atrophy (Atrophic Vaginitis) 41

5.3 Vasomotor Symptoms of Menopause (Hot Flashes) 43

6 Dormant Projects 46

6.1 Post Menopausal Osteoporosis 46

6.2 Vaginal Atrophy (Atrophic Vaginitis) 47

6.3 Vasomotor Symptoms of Menopause (Hot Flashes) 48

7 Discontinued Products 49

7.1 Post Menopausal Osteoporosis 49

7.2 Vasomotor Symptoms of Menopause (Hot Flashes) 49

8 Product Development Milestones 50

8.1 Post Menopausal Osteoporosis 50

8.2 Vaginal Atrophy (Atrophic Vaginitis) 65

8.3 Vasomotor Symptoms of Menopause (Hot Flashes) 68

9 Appendix 83

9.1 Methodology 83

9.2 Coverage 83

9.3 Secondary Research 83

9.4 Primary Research 83

9.5 Expert Panel Validation 83

9.6 Contact Us 84

9.7 Disclaimer 84

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Number of Products under Development for Post Menopausal Osteoporosis 8

Figure 2: Number of Products under Development by Companies, Post Menopausal Osteoporosis 9

Figure 3: Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) 12

Figure 4: Number of Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 13

Figure 5: Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes) 15

Figure 6: Number of Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 16

Figure 7: Number of Products by Targets, Post Menopausal Osteoporosis 18

Figure 8: Number of Products by Stage and Targets, Post Menopausal Osteoporosis 18

Figure 9: Number of Products by Mechanism of Actions, Post Menopausal Osteoporosis 19

Figure 10: Number of Products by Stage and Mechanism of Actions, Post Menopausal Osteoporosis 20

Figure 11: Number of Products by Routes of Administration, Post Menopausal Osteoporosis 21

Figure 12: Number of Products by Stage and Routes of Administration, Post Menopausal Osteoporosis 21

Figure 13: Number of Products by Molecule Types, Post Menopausal Osteoporosis 22

Figure 14: Number of Products by Stage and Molecule Types, Post Menopausal Osteoporosis 23

Figure 15: Number of Products by Targets, Vaginal Atrophy (Atrophic Vaginitis) 24

Figure 16: Number of Products by Stage and Targets, Vaginal Atrophy (Atrophic Vaginitis) 24

Figure 17: Number of Products by Mechanism of Actions, Vaginal Atrophy (Atrophic Vaginitis) 25

Figure 18: Number of Products by Stage and Mechanism of Actions, Vaginal Atrophy (Atrophic Vaginitis) 26

Figure 19: Number of Products by Routes of Administration, Vaginal Atrophy (Atrophic Vaginitis) 27

Figure 20: Number of Products by Stage and Routes of Administration, Vaginal Atrophy (Atrophic Vaginitis) 27

Figure 21: Number of Products by Stage and Molecule Types, Vaginal Atrophy (Atrophic Vaginitis) 28

Figure 22: Number of Products by Targets, Vasomotor Symptoms of Menopause (Hot Flashes) 29

Figure 23: Number of Products by Stage and Targets, Vasomotor Symptoms of Menopause (Hot Flashes) 29

Figure 24: Number of Products by Mechanism of Actions, Vasomotor Symptoms of Menopause (Hot Flashes) 30

Figure 25: Number of Products by Stage and Mechanism of Actions, Vasomotor Symptoms of Menopause (Hot Flashes) 31

Figure 26: Number of Products by Routes of Administration, Vasomotor Symptoms of Menopause (Hot Flashes) 32

Figure 27: Number of Products by Stage and Routes of Administration, Vasomotor Symptoms of Menopause (Hot Flashes) 32

Figure 28: Number of Products by Molecule Types, Vasomotor Symptoms of Menopause (Hot Flashes) 33

Figure 29: Number of Products by Stage and Molecule Types, Vasomotor Symptoms of Menopause (Hot Flashes) 34

1.1 List of Tables

Table 1: Number of Products under Development for Post Menopausal Osteoporosis 8

Table 2: Number of Products under Development by Companies, Post Menopausal Osteoporosis 9

Table 3: Products under Development by Companies, Post Menopausal Osteoporosis 10

Table 4: Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) 12

Table 5: Number of Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 13

Table 6: Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis) 14

Table 7: Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes) 15

Table 8: Number of Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 16

Table 9: Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes) 17

Table 10: Number of Products by Stage and Target, Post Menopausal Osteoporosis 19

Table 11: Number of Products by Stage and Mechanism of Action, Post Menopausal Osteoporosis 20

Table 12: Number of Products by Stage and Route of Administration, Post Menopausal Osteoporosis 22

Table 13: Number of Products by Stage and Molecule Type, Post Menopausal Osteoporosis 23

Table 14: Number of Products by Stage and Target, Vaginal Atrophy (Atrophic Vaginitis) 25

Table 15: Number of Products by Stage and Mechanism of Action, Vaginal Atrophy (Atrophic Vaginitis) 26

Table 16: Number of Products by Stage and Route of Administration, Vaginal Atrophy (Atrophic Vaginitis) 28

Table 17: Number of Products by Stage and Molecule Type, Vaginal Atrophy (Atrophic Vaginitis) 28

Table 18: Number of Products by Stage and Target, Vasomotor Symptoms of Menopause (Hot Flashes) 30

Table 19: Number of Products by Stage and Mechanism of Action, Vasomotor Symptoms of Menopause (Hot Flashes) 31

Table 20: Number of Products by Stage and Route of Administration, Vasomotor Symptoms of Menopause (Hot Flashes) 33

Table 21: Number of Products by Stage and Molecule Type, Vasomotor Symptoms of Menopause (Hot Flashes) 34

Table 22: Post Menopausal Osteoporosis-Pipeline by Amgen Inc, 35

Table 23: Post Menopausal Osteoporosis-Pipeline by Enteris BioPharma Inc, 36

Table 24: Post Menopausal Osteoporosis-Pipeline by GL Pharm Tech Corp, 36

Table 25: Post Menopausal Osteoporosis-Pipeline by Intas Pharmaceuticals Ltd, 37

Table 26: Post Menopausal Osteoporosis-Pipeline by Ipsen SA, 37

Table 27: Post Menopausal Osteoporosis-Pipeline by Lupin Ltd, 38

Table 28: Post Menopausal Osteoporosis-Pipeline by Luye Pharma Group Ltd, 38

Table 29: Post Menopausal Osteoporosis-Pipeline by NIBEC, 39

Table 30: Post Menopausal Osteoporosis-Pipeline by Oncobiologics Inc, 39

Table 31: Post Menopausal Osteoporosis-Pipeline by Paras Biopharmaceuticals Finland Oy, 40

Table 32: Post Menopausal Osteoporosis-Pipeline by Uni-Bio Science Group Ltd, 40

Table 33: Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Ligand Pharmaceuticals Inc, 41

Table 34: Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Medinova AG, 41

Table 35: Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Mithra Pharmaceuticals SA, 42

Table 36: Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by TherapeuticsMD Inc, 42

Table 37: Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by EndoCeutics Inc, 43

Table 38: Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by MenoGeniX Inc, 43

Table 39: Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Mithra Pharmaceuticals SA, 44

Table 40: Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Ogeda SA, 44

Table 41: Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Pherin Pharmaceuticals Inc, 45

Table 42: Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by TherapeuticsMD Inc, 45

Table 43: Post Menopausal Osteoporosis-Dormant Projects, 46

Table 44: Vaginal Atrophy (Atrophic Vaginitis)-Dormant Projects, 47

Table 45: Vasomotor Symptoms of Menopause (Hot Flashes)-Dormant Projects, 48

Table 46: Post Menopausal Osteoporosis-Discontinued Products, 49

Table 47: Vasomotor Symptoms of Menopause (Hot Flashes)-Discontinued Products, 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Amgen Inc

EndoCeutics Inc

Enteris BioPharma Inc

GL Pharm Tech Corp

Intas Pharmaceuticals Ltd

Ipsen SA

Ligand Pharmaceuticals Inc

Lupin Ltd

Luye Pharma Group Ltd

Medinova AG

MenoGeniX Inc

Mithra Pharmaceuticals SA

NIBEC

Ogeda SA

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Uni-Bio Science Group Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand